Novavax, Inc. (NASDAQ:NVAX) Insider Gregory M. Glenn Sells 8,250 Shares

Novavax, Inc. (NASDAQ:NVAX) insider Gregory M. Glenn sold 8,250 shares of Novavax stock in a transaction that occurred on Tuesday, November 23rd. The shares were sold at an average price of $199.50, for a total transaction of $1,645,875.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Gregory M. Glenn also recently made the following trade(s):

  • On Wednesday, September 15th, Gregory M. Glenn sold 1,183 shares of Novavax stock. The shares were sold at an average price of $229.34, for a total transaction of $271,309.22.
  • On Tuesday, August 31st, Gregory M. Glenn sold 1,386 shares of Novavax stock. The stock was sold at an average price of $239.87, for a total transaction of $332,459.82.

NVAX stock opened at $200.07 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.24 and a quick ratio of 1.43. The company has a fifty day moving average price of $181.58 and a two-hundred day moving average price of $193.04. Novavax, Inc. has a one year low of $94.67 and a one year high of $331.68. The stock has a market cap of $15.13 billion, a price-to-earnings ratio of -13.51 and a beta of 1.28.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported ($4.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($4.04) by ($0.27). Novavax had a negative return on equity of 149.66% and a negative net margin of 89.31%. The company had revenue of $178.80 million for the quarter, compared to the consensus estimate of $347.34 million. During the same period last year, the firm earned ($3.21) earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. Research analysts anticipate that Novavax, Inc. will post -11.84 EPS for the current fiscal year.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating and set a $246.00 target price on the stock in a report on Thursday, August 12th. Chardan Capital restated a “neutral” rating on shares of Novavax in a report on Wednesday, September 1st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Novavax presently has an average rating of “Buy” and an average target price of $249.00.

A number of hedge funds have recently added to or reduced their stakes in NVAX. Capital World Investors boosted its position in Novavax by 139.3% during the third quarter. Capital World Investors now owns 1,478,701 shares of the biopharmaceutical company’s stock worth $306,550,000 after purchasing an additional 860,867 shares during the period. Vanguard Group Inc. boosted its position in shares of Novavax by 13.2% in the second quarter. Vanguard Group Inc. now owns 6,670,660 shares of the biopharmaceutical company’s stock valued at $1,416,249,000 after acquiring an additional 777,356 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Novavax in the third quarter valued at about $64,873,000. State Street Corp boosted its position in shares of Novavax by 17.4% in the second quarter. State Street Corp now owns 1,693,390 shares of the biopharmaceutical company’s stock valued at $359,524,000 after acquiring an additional 251,437 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Novavax in the second quarter valued at about $40,016,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Further Reading: What is a stock buyback?

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.